Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alejandro Betancourt

Neuromusculoskeletal Medicine & OMM Harlingen, TX Medical Doctor

NPI 1528129228 CMS profile 68495

597 W. Sesame Dr., Suite D., Harlingen, TX 78550

Open in the dashboard

General payments

$4,347

247 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alejandro Betancourt of Harlingen, TX is reported in the CMS Open Payments database as having received $4,347 across 247 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Neuromusculoskeletal Medicine & OMM profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $959 11
2023 General $468 23
2022 General $728 26
2021 General $603 53
2020 General $587 49
2019 General $1,001 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alejandro Betancourt
  • Neuromusculoskeletal Medicine & OMM median
  • Middle half of Neuromusculoskeletal Medicine & OMM
  • National median

In program year 2025, general payments to Alejandro Betancourt were reported at $959. Among 217 Neuromusculoskeletal Medicine & OMM profiles paid that year, the median was $119 and the middle half received between $36 and $380.

Show as a table
Year Alejandro Betancourt Neuromusculoskeletal Medicine & OMM median Middle half National median
2019 $1,001 $92 $27–$283 $163
2020 $587 $85 $20–$411 $114
2021 $603 $120 $32–$548 $132
2022 $728 $96 $32–$518 $149
2023 $468 $92 $33–$328 $160
2024 $0 $122 $35–$378 $164
2025 $959 $119 $36–$380 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $1,055 15 payments
  2. Medtronic USA, Inc. $798 123 payments
  3. Medtronic, Inc. $719 50 payments
  4. Boston Scientific Corporation $429 38 payments
  5. MML US, Inc. $347 3 payments
  6. Stryker Corporation $310 2 payments
  7. SI-BONE, Inc. $223 5 payments
  8. Acumed LLC $117 3 payments
  9. Acera Surgical, Inc. $73 1 payment
  10. Integra LifeSciences Corporation $64 1 payment
  11. Other $211 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,388 241 payments
  2. Travel and Lodging $914 5 payments
  3. Gift $44 1 payment
Products named General payments · program years 2019–2025
  1. INTELLIS Spinal Cord Neurostimulation $604 77 payments
  2. Proclaim Family of SCS IPGs $493 3 payments
  3. ReActiv8 $347 3 payments
  4. PROCLAIM $347 5 payments
  5. O-ARM $311 2 payments
  6. MILD DEVICE KIT $310 2 payments
  7. INTELLIS Spinal Cord Neurostimulation $239 30 payments
  8. IFUSE IMPLANT $189 3 payments
  9. ACTIVA $147 44 payments
  10. GENERAL PAIN MANAGEMENT $144 9 payments
  11. Other $1,265 58 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

430

Median for Neurosurgery: 83

Drug cost

$3,999

Median for Neurosurgery: $872

Branded share of claims

37.4%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Acetaminophen-Codeine Acetaminophen With Codeine Brand 114 $1,160
Tizanidine Hcl Generic 26 $917
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 47 $568
Gabapentin Generic 39 $463
Cephalexin Generic 76 $243
Levetiracetam Generic 14 $196
Ibuprofen Generic 14 $161
Tramadol Hcl Generic 41 $151
Meloxicam Generic 59 $140

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$106,661

Medicare's payments for the services billed

Medicare patients

259

Average age 74

Services billed

526

146 women, 113 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 73%
Diabetes 53%
Ischemic heart disease 40%
Chronic kidney disease 38%
Depression 34%
Heart failure 29%
Osteoporosis 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

247 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neuromusculoskeletal Medicine & OMM in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record